Comparative Pharmacology
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE.
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE vs TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
Trimethobenzamide is a centrally acting antiemetic that inhibits the chemoreceptor trigger zone (CTZ) in the medulla oblongata by suppressing emetic stimuli. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and possibly serotonin 5-HT3 receptors.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
300 mg orally or intramuscularly 3 to 4 times daily as needed for nausea and vomiting.
None Documented
None Documented
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Terminal elimination half-life approximately 7-9 hours in adults; prolonged in renal impairment (up to 20-30 hours).
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Primarily renal (50-70% as unchanged drug and metabolites) and biliary (~20-30%); less than 5% fecal.
Category A/B
Category C
Antihistamine / Antiemetic
Antiemetic